Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    NCT00177866
Previous Study | Return to List | Next Study

Safety of Celecoxib in Patients With Crohn's Disease

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT00177866
Recruitment Status : Terminated (We were unable to get additional funding to complete study.)
First Posted : September 15, 2005
Results First Posted : July 15, 2016
Last Update Posted : August 29, 2016
Sponsor:
Collaborators:
Shadyside Hospital Foundation
Pfizer
Information provided by (Responsible Party):
University of Pittsburgh

Tracking Information
First Submitted Date  ICMJE September 13, 2005
First Posted Date  ICMJE September 15, 2005
Results First Submitted Date  ICMJE June 15, 2016
Results First Posted Date  ICMJE July 15, 2016
Last Update Posted Date August 29, 2016
Study Start Date  ICMJE December 2003
Actual Primary Completion Date June 2010   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: June 15, 2016)
Change in Crohn's Disease Activity Index (CDAI) Scores in Response to Treatment [ Time Frame: completion of all study participants ]
Change in Crohn's Disease Activity Index (CDAI) scores in response to treatment
Original Primary Outcome Measures  ICMJE
 (submitted: September 13, 2005)
Change of CDAI scores in response to treatment.
Change History
Current Secondary Outcome Measures  ICMJE
 (submitted: June 15, 2016)
Change in Short Inflammatory Bowel Disease Questionnaire (SIBDQ) Scores in Response to Treatment [ Time Frame: completion of all study participants ]
No results or publication, data destroyed due to age of study.
Original Secondary Outcome Measures  ICMJE
 (submitted: September 13, 2005)
Change of Short Inflammatory Bowel Disease Questionnaire (SIBDQ) scores in response to treatment.
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE Safety of Celecoxib in Patients With Crohn's Disease
Official Title  ICMJE The Safety of Celecoxib (Celebrex) in Patients With Crohn's Disease
Brief Summary The investigators will select 60 people who are 18-70 years of age with Crohn's disease and randomly assign them to receive an 8-week trial of celecoxib and an 8-week trial of a placebo. There will be a 1-week interval or "wash-out" between trials when the participant does not take any study medication. The investigators will monitor the participants for 18 weeks after they start the medication and observe their Crohn's disease activity, assessing for flare-ups or exacerbations in the disease and other possible side effects of celecoxib. Based on these observations, a determination will be made by the investigators as to the safety of celecoxib. If celecoxib is found to be safe, then it may provide physicians with a medication that they can prescribe for people who have Crohn's disease and experience chronic pain from arthritis and arthralgia.
Detailed Description Please refer to brief summary (above).
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 4
Study Design  ICMJE Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
Condition  ICMJE Crohn's Disease
Intervention  ICMJE
  • Drug: Celebrex
    Celebrex 200 mg PO BID for the first 8 weeks, followed by a 1 week "washout period" then placebo PO BID for the remaining 8 weeks - or - placebo PO BID for the first 8 weeks, followed by a 1 week "washout period" then Celebrex 200 mg PO BID for the remaining 8 weeks.
    Other Name: Celecoxib (brand name)
  • Drug: placebo
    placebo PO BID for either the first eight weeks or the last eight weeks of the study.
Study Arms  ICMJE
  • Active Comparator: A Placebo or Celebrex
    either placebo PO BID for the first eight weeks or Celebrex 200 mg PO BID for the first eight weeks
    Intervention: Drug: Celebrex
  • Placebo Comparator: B Placebo or Celebrex
    either placebo PO BID for the last eight weeks or Celebrex 200 mg PO BID for the last eight weeks
    Intervention: Drug: placebo
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Terminated
Actual Enrollment  ICMJE
 (submitted: September 23, 2010)
28
Original Enrollment  ICMJE
 (submitted: September 13, 2005)
60
Actual Study Completion Date  ICMJE June 2010
Actual Primary Completion Date June 2010   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  1. Greater than 18 years of age or less than 70 years of age
  2. Confirmed diagnosis of Crohn's disease
  3. Inactive disease (CDAI scores at baseline <150) or active disease (CDAI scores at baseline <200).

Exclusion Criteria:

  1. Pregnant, nursing mothers and women of childbearing potential who are not using reliable contraception (i.e.: oral contraceptive pill [OCP], intrauterine device [IUD], Norplant)
  2. Enrolled in any other study involving non-steroidal anti-inflammatory drug (NSAID) medications
  3. NSAID use at time of study
  4. Baseline moderate to severe Crohn's disease activity (CDAI > 200)
  5. Current treatment of less than 6 months with mercaptopurine (6 MP) or immuran.
  6. Treatment with current Crohn's medication for a period of less than 3 months
  7. Surgery for Crohn's disease (within 1 month)
  8. Known sensitivity to celecoxib, NSAIDs, or sulfonamides
  9. History of gastritis, gastrointestinal bleeding, or peptic ulcer disease
  10. Advanced kidney disease
  11. Severe hepatic impairment
  12. Subjects currently taking angiotensin-converting enzyme (ACE) inhibitors, furosemide, fluconazole, lithium, corticosteroids, and warfarin
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 18 Years to 70 Years   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE Not Provided
Removed Location Countries United States
 
Administrative Information
NCT Number  ICMJE NCT00177866
Other Study ID Numbers  ICMJE 0312013
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible Party University of Pittsburgh
Study Sponsor  ICMJE University of Pittsburgh
Collaborators  ICMJE
  • Shadyside Hospital Foundation
  • Pfizer
Investigators  ICMJE
Principal Investigator: George L Arnold, MD University of Pittsburgh
PRS Account University of Pittsburgh
Verification Date June 2016

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP